Evidence map›Paper›PMID 29967134›Full record

ArticleJournal of medical genetics2019

Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.

Dongming Chen, Wei Chen, Yong Xu, Meng Zhu, Yi Xiao, Yanhao Shen, Shuai Zhu, Changchun Cao, Xianlin Xu

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Journal of medical genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Current perspective on the impact of endogenous retroviruses in clear cell renal cell carcinoma.Kidney cancer journal : official journal of the Kidney Cancer Association · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dongming Chen *Department of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Wei Chen *Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yong Xu *Department of Nephrology, Huai'an Second People's Hospital and the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Meng ZhuDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Yi XiaoDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Yanhao ShenDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Shuai ZhuDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Changchun CaoDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.
Xianlin XuDepartment of Urology, The Affiliated Sir Run Run Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0002-4422-6832
Nanjing Medical University · CNShanghai Jiao Tong University · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is a malignant urogenital cancer with high mortality; however, current progress in understanding its molecular mechanism and predicting clinical treatment outcome is limited. Therefore, this study is to evaluate the clinical significance of immune inhibitory molecular human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) in ccRCC prognosis and transcriptional regulatory network.

methodsExpression of

resultsIt was shown that expression of HHLA2 was statistically significantly increased in ccRCC tissues compared with normal renal tissues at both transcriptional and protein level. Moreover, the expression of HHLA2 was closely correlated with multiple clinicopathological features including tumour size, clinical stage and histological grade. High HHLA2 expression was associated with poor overall survival and clinical outcome. Comprehensive microarray analysis further identified thousands of HHLA2 targets including mRNA, long non-coding RNA and circular RNA that might function in various biological processes, especially, immune response.

conclusionIncreased HHLA2 expression was observed in ccRCC tumour tissue, which leads to a remarkable shorter overall survival and poorer prognosis. Together with other molecular evidence, we have demonstrated that HHLA2 could be a potential prognostic biomarker for ccRCC.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticAdultAgedCarcinoma, Renal CellCell Line, TumorComputational BiologyFemaleGene Expression ProfilingHumansImmunoglobulinsImmunohistochemistryKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedBiomarkers, TumorHHLA2 protein, humanImmunoglobulinscircrnaclear cell renal cell carcinomaHhla2lncrnaMrna

Identifiers

PMID29967134
OpenAlexW2809829154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.